Aphria (NASDAQ: APHA) is one of 33 public companies in the “Medicinals & botanicals” industry, but how does it compare to its competitors? We will compare Aphria to similar businesses based on the strength of its profitability, risk, analyst recommendations, earnings, institutional ownership, valuation and dividends.

Analyst Recommendations

This is a summary of current ratings and price targets for Aphria and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aphria 0 0 1 0 3.00
Aphria Competitors 136 360 407 14 2.33

Aphria presently has a consensus target price of $15.50, suggesting a potential upside of 169.57%. As a group, “Medicinals & botanicals” companies have a potential upside of 88.72%. Given Aphria’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Aphria is more favorable than its competitors.

Insider & Institutional Ownership

11.3% of Aphria shares are owned by institutional investors. Comparatively, 21.6% of shares of all “Medicinals & botanicals” companies are owned by institutional investors. 25.8% of shares of all “Medicinals & botanicals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Aphria and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Aphria -14.89% -2.05% -1.47%
Aphria Competitors -163.69% -267.59% -46.37%

Earnings & Valuation

This table compares Aphria and its competitors revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Aphria $405.96 million -$63.21 million -95.83
Aphria Competitors $218.50 million -$99.79 million -0.52

Aphria has higher revenue and earnings than its competitors. Aphria is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Volatility and Risk

Aphria has a beta of 2.12, meaning that its stock price is 112% more volatile than the S&P 500. Comparatively, Aphria’s competitors have a beta of 2.56, meaning that their average stock price is 156% more volatile than the S&P 500.

Summary

Aphria beats its competitors on 8 of the 13 factors compared.

About Aphria

Aphria Inc. cultivates, processes, produces, markets, distributes, and sells medical cannabis in Canada and internationally. The company offers pharmaceutical-grade medical cannabis, adult-use cannabis, and cannabis-derived extracts and derivative cannabis products under the Solei, RIFF, Good Supply, Aphria, P'tite Pof, and Broken Coast brands. It serves patients and consumers through distributors and online. The company is headquartered in Leamington, Canada.

Receive News & Ratings for Aphria Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aphria and related companies with MarketBeat.com's FREE daily email newsletter.